Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof

A method for reducing the growth of a cancer cell comprising administering to a subject in need thereof an effective amount of a compound represented by the general formula (I), and its pharmaceutically acceptable salt or stereoisomer thereof:

• wherein:
• R1 is selected from the following groups that are unsubstituted or substituted by 1-3 same or different Q1:
• C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-8cycloalkyl-C0-6alkyl, 6-10-membered fused ring-C0-6alkyl, 7-10-membered spiro ring-C0-6 alkyl and 7-10-membered bridged ring-C0-6alkyl, and the carbon atom in said cycloalkyl, said fused ring, said spiro ring, said bridged ring may be optionally replaced by 1-3 same or different groups consisting of O, S(O)m, N(H)n and/or C(O),
• Q1 is selected from the groups consisting of halogen, hydroxy, amino, carboxyl, cyano, C1-6alkyl, C1-6alkoxyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkylcarbonyloxy, C1-4alkoxylcarbonyl, C1-6alkylacylamino, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonylamino and C3-8cycloalkyl;
• R2 is selected from the following groups that are unsubstituted or substituted by 1-2 same or different Q2:
• C3-4cycloalkyl-C0-6alkyl, 6-10-membered fused ring-C0-6alkyl, 7-10-membered spiro ring-C0-6alkyl and 7-10-membered bridged ring-C0-6alkyl, and the carbon atom in said cycloalkyl, said fused ring, said spiro ring and said bridged ring may be replaced by 1-3 same or different groups consisting of O, S(O)m, N(H)n and/or C(O), provided that an ester structure “—O—C(O)—” is not present in the replaced ring and when R2 is 7-10-membered bridged ring-C0-6alkyl, R1 is not C3-4cycloalkyl-C0-6alkyl or C1-6alkyl;
• Q2 is selected from the groups consisting of halogen, hydroxy, amino, carboxyl, cyano, nitro, trifluoromethyl, C1-6alkyl, C1-6alkoxyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkylcarbonyloxy, C1-6alkoxylcarbonyl, C1-6alkylacylamino, C1-6alkylsulfonyl, C1-6alkylsulfinyl and C1-6alkylsulfonylamino;
• R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6 alkyl substituted with halogen and C1-6alkoxyl substituted with halogen, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkylthio, C1-6alkylcarbamoyl, C1-6alkylcarbonyl, C1-6alkoxylcarbonyl, C1-6alkylcarbonyloxy, C1-6alkylacylamino, C1-6alkylsulfonyl, C1-6alkylsulfinyl and C1-6alkylsulfonylamino;
• R3′ is absent;
• R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, C1-6alkyl, C1-6alkoxyl, C1-6alkyl substituted with halogen and C1-6alkoxyl substituted with halogen, C1-6alkylamino and di(C1-6alkyl)amino;
• X is selected from the group consisting of cyano-substituted methenyl or a nitrogen atom;
• L is selected from the group consisting of O, S(O)m, N(H), N(CH3) or C(O);
• T is selected from the group consisting of a covalent bond, C(O) or CH(R′), R′ is selected from the group consisting of hydrogen or C1-6alkyl;
• Z is hydrogen;
• q is 2, and R3 may be identical or different;
• m is selected from the group consisting of 0, 1 or 2;
• and
• n is selected from the group consisting of 0 or 1, wherein the cancer cell is selected from the group consisting of cerebroma, lung cancer, squamous cell carcinoma, bladder carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, mammary cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, adenocarcinoma of esophagus, esophageal squamous cell cancer and prostate carcinoma.